AGIOS PHARMACEUTICALS, INC. Payments to Acquire Available-for-sale Securities
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Payments to Acquire Available-for-sale Securities of $933.32 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2019-02-14
- AGIOS PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $84.18M, a 39.21% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $135.97M, a 3.77% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-06-30 was $441.82M, a 2820.90% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-03-31 was $26.74M, a 87.34% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2018 was $933.32M, a 35.52% increase from fiscal 2017.
- AGIOS PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2017 was $688.70M, a 36.09% increase from fiscal 2016.
- AGIOS PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2016 was $506.07M, a 43.29% increase from fiscal 2015.
- AGIOS PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2015 was $353.18M, a 57.82% decline from fiscal 2014.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2018-12-31 | $933.32M 10-K · filed 2019-02-14 | |||
| 2017-12-31 | $84.18M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $220.15M derived: sum of 2 quarters · filed 2019-02-14 | $661.96M derived: sum of 3 quarters · filed 2019-02-14 | $688.70M 10-K · filed 2019-02-14 |
| 2017-09-30 | $135.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $577.78M derived: sum of 2 quarters · filed 2017-11-01 | $604.52M 10-Q · filed 2017-11-01 | $743.00M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-06-30 | $441.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $468.56M 10-Q · filed 2017-08-08 | $607.04M derived: sum of 3 quarters · filed 2019-02-14 | $748.33M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-03-31 | $26.74M 10-Q · filed 2017-05-04 | $165.22M derived: sum of 2 quarters · filed 2019-02-14 | $306.52M derived: sum of 3 quarters · filed 2019-02-14 | $321.64M derived: sum of 4 quarters · filed 2019-02-14 |
| 2016-12-31 | $138.48M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $279.78M derived: sum of 2 quarters · filed 2019-02-14 | $294.90M derived: sum of 3 quarters · filed 2019-02-14 | $506.07M 10-K · filed 2019-02-14 |
| 2016-09-30 | $141.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $156.42M derived: sum of 2 quarters · filed 2017-11-01 | $367.59M 10-Q · filed 2017-11-01 | $502.11M derived: sum of 4 quarters · filed 2018-02-14 |
| 2016-06-30 | $15.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $226.29M 10-Q · filed 2017-08-08 | $360.81M derived: sum of 3 quarters · filed 2018-02-14 | $473.26M derived: sum of 4 quarters · filed 2018-02-14 |
| 2016-03-31 | $211.16M 10-Q · filed 2017-05-04 | $345.68M derived: sum of 2 quarters · filed 2018-02-14 | $458.13M derived: sum of 3 quarters · filed 2018-02-14 | $528.81M derived: sum of 4 quarters · filed 2018-02-14 |
| 2015-12-31 | $134.52M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | $246.97M derived: sum of 2 quarters · filed 2018-02-14 | $317.65M derived: sum of 3 quarters · filed 2018-02-14 | $353.18M 10-K · filed 2018-02-14 |
| 2015-09-30 | $112.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $183.13M derived: sum of 2 quarters · filed 2016-11-03 | $218.66M 10-Q · filed 2016-11-03 | $840.49M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-06-30 | $70.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $106.20M 10-Q · filed 2016-08-08 | $728.04M derived: sum of 3 quarters · filed 2017-02-16 | $817.09M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-03-31 | $35.53M 10-Q · filed 2016-05-09 | $657.36M derived: sum of 2 quarters · filed 2017-02-16 | $746.41M derived: sum of 3 quarters · filed 2017-02-16 | $837.93M derived: sum of 4 quarters · filed 2017-02-16 |
| 2014-12-31 | $621.84M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $710.88M derived: sum of 2 quarters · filed 2017-02-16 | $802.41M derived: sum of 3 quarters · filed 2017-02-16 | $837.22M 10-K · filed 2017-02-16 |
| 2014-09-30 | $89.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $180.57M derived: sum of 2 quarters · filed 2015-11-06 | $215.38M 10-Q · filed 2015-11-06 | $241.93M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | $91.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $126.34M 10-Q · filed 2015-08-07 | $152.89M derived: sum of 3 quarters · filed 2016-02-26 | $249.19M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | $34.81M 10-Q · filed 2015-05-11 | $61.36M derived: sum of 2 quarters · filed 2016-02-26 | $157.67M derived: sum of 3 quarters · filed 2016-02-26 | $164.95M derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | $26.55M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $122.85M derived: sum of 2 quarters · filed 2016-02-26 | $130.13M derived: sum of 3 quarters · filed 2016-02-26 | $146.05M 10-K · filed 2016-02-26 |
| 2013-09-30 | $96.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $103.58M derived: sum of 2 quarters · filed 2014-11-07 | $119.50M 10-Q · filed 2014-11-07 | $136.91M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $7.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $23.20M 10-Q · filed 2014-08-07 | $40.61M derived: sum of 3 quarters · filed 2015-02-24 | $61.07M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $15.91M 10-Q · filed 2014-05-09 | $33.33M derived: sum of 2 quarters · filed 2015-02-24 | $53.79M derived: sum of 3 quarters · filed 2015-02-24 | |
| 2012-12-31 | $17.41M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $37.88M derived: sum of 2 quarters · filed 2015-02-24 | $88.52M 10-K · filed 2015-02-24 | |
| 2012-09-30 | $20.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $71.11M 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | $50.65M 10-Q · filed 2013-09-05 | |||
| 2011-12-31 | $105.94M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |